KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Average: 2011-2025

Historic Equity Average for TherapeuticsMD (TXMD) over the last 10 years, with Sep 2025 value amounting to $27.4 million.

  • TherapeuticsMD's Equity Average fell 0.05% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year decrease of 0.05%. This contributed to the annual value of $28.3 million for FY2024, which is 12.06% down from last year.
  • TherapeuticsMD's Equity Average amounted to $27.4 million in Q3 2025, which was up 1.30% from $27.0 million recorded in Q2 2025.
  • TherapeuticsMD's Equity Average's 5-year high stood at $33.6 million during Q1 2023, with a 5-year trough of -$117.1 million in Q1 2022.
  • For the 3-year period, TherapeuticsMD's Equity Average averaged around $28.8 million, with its median value being $28.2 million (2024).
  • As far as peak fluctuations go, TherapeuticsMD's Equity Average crashed by 270.69% in 2021, and later soared by 536.77% in 2023.
  • TherapeuticsMD's Equity Average (Quarterly) stood at -$75.5 million in 2021, then surged by 91.30% to -$6.6 million in 2022, then spiked by 536.77% to $28.7 million in 2023, then declined by 5.01% to $27.2 million in 2024, then declined by 0.05% to $27.4 million in 2025.
  • Its Equity Average was $27.4 million in Q3 2025, compared to $27.0 million in Q2 2025 and $27.1 million in Q1 2025.